Welcome to our dedicated page for Aethlon Medical SEC filings (Ticker: AEMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aethlon Medical, Inc. (Nasdaq: AEMD) SEC filings page on Stock Titan brings together the company’s U.S. regulatory documents, giving investors direct access to the disclosures that frame its clinical and financial profile. Aethlon is a clinical-stage medical device company based in San Diego, California, focused on developing the investigational Hemopurifier to address unmet needs in oncology and life-threatening infectious diseases.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Aethlon’s business, risk factors, Hemopurifier development programs, and financial condition. Current reports on Form 8-K provide detail on material events such as public offerings and private placements of common stock and warrants, reverse stock split actions, Nasdaq listing notices and compliance updates, and key clinical and corporate announcements referenced in company press releases.
For those tracking AEMD’s capital structure, registration statements on Form S-1 and related amendments outline the terms of securities offerings, including common stock, pre-funded warrants, and common stock purchase warrants, as well as associated registration rights. These filings explain how many shares and warrants are being registered, exercise prices and durations, and the company’s stated use of proceeds for working capital, clinical trial expenses, research and development, and other corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight key elements of lengthy documents, helping readers quickly identify items such as Hemopurifier development disclosures, Nasdaq listing discussions, and financing terms. Real-time updates from EDGAR ensure that new Aethlon Medical filings appear promptly, while dedicated sections make it easier to locate material 8-Ks, registration statements, and periodic reports relevant to AEMD’s evolving clinical-stage strategy.
Aethlon Medical director Chetan Shah reported a tax-related share forfeiture tied to equity compensation. On conversion of 268 vested restricted stock units into common stock, he forfeited 178 shares at $2.19 per share to cover tax withholdings, based on the market price at the time.
Following this non-market transaction, Shah directly holds 1,463 shares of Aethlon Medical common stock. The disposition reflects routine tax settlement rather than an open-market sale or purchase decision.
Aethlon Medical director Nicolas Gikakis reported a tax-related share forfeiture. On the conversion of 268 vested restricted stock units into common stock, he forfeited 178 shares to cover tax withholdings, using a market price of $2.19 per share. Following the disposition, he holds 1,464 common shares directly.
Aethlon Medical director Edward G. Broenniman reported a routine tax-withholding disposition related to restricted stock units. He forfeited 89 shares of common stock, valued at $2.19 per share, to cover taxes upon conversion of 357 vested RSUs. After this transaction, he directly holds 1,915 shares.
Aethlon Medical, Inc. reported that, following recent exercises of certain pre-funded warrants, it has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026. The company stated that all previously outstanding pre-funded warrants have now been exercised, simplifying its capital structure by converting those warrant rights into common shares.
Aethlon Medical, Inc. held its Annual Meeting on February 19, 2026, where stockholders approved several measures that significantly expand the company’s equity capacity. The Articles of Incorporation were amended to increase authorized common stock from 6,000,000 to 100,000,000 shares.
Stockholders also approved adding 100,000 shares to the 2020 Equity Incentive Plan and ratified Haskell & White LLP as auditor for the year ending March 31, 2026. For Nasdaq Listing Rule 5635(d) purposes, stockholders approved the potential issuance of up to 1,662,553 shares of common stock tied to various warrants under a Securities Purchase Agreement dated December 5, 2025, and up to 368,471 shares issuable upon exercise of additional warrants from a Warrant Inducement Agreement. The meeting had a quorum, with 556,359 of 973,213 outstanding shares represented.
AETHLON MEDICAL INC Schedule 13G reports beneficial ownership of 84,496 shares, equal to 9.99% of the common stock as of 12/31/2025.
The filing states Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., and that Armistice Capital and Steven Boyd may be deemed to beneficially own these shares through voting and dispositive power under an Investment Management Agreement.
Aethlon Medical (Common Stock) ownership update: Alumni Capital LP, Alumni Capital GP LLC and Ashkan Mapar report shared beneficial ownership of 55,555 shares, representing 4.05% of the class. The shares relate to rights under a Securities Purchase Agreement dated September 4, 2025 and a Common Warrant dated September 4, 2025. The percent of class is calculated using 1,315,110 Shares outstanding as of February 11, 2026 as referenced in the issuer's Form 10-Q. The filing states that as of February 12, 2026 the Reporting Persons do not beneficially own more than five percent of the outstanding Shares.
Aethlon Medical reported a quarterly net loss of $2.0 million for the three months ended December 31, 2025, slightly wider than a year earlier, while the nine‑month net loss improved to $5.3 million from $7.1 million. Operating expenses fell over the nine‑month period as payroll, general and administrative costs, and professional fees declined.
Cash, cash equivalents and restricted cash rose to $7.1 million, helped by equity financings and warrant exercises, but management states this cash is not sufficient to fund operations for at least twelve months, creating substantial doubt about the company’s ability to continue as a going concern. To address this, Aethlon completed a December 2025 private placement of pre‑funded and common warrants with gross proceeds of about $3.3 million and executed a warrant inducement that generated additional cash.
Clinically, the company is advancing its Hemopurifier device, designated by the FDA as a Breakthrough Device for certain cancers and life‑threatening viruses. The first oncology cohort in an Australian solid‑tumor trial (three patients) showed a favorable safety profile with no serious device‑related events, and enrollment has begun in a second cohort where patients receive two treatments. A planned Indian oncology trial was cancelled to conserve resources. Preclinical studies, released as non‑peer‑reviewed preprints, showed high removal of disease‑related extracellular vesicles, supporting future research directions but not yet clinical outcomes.
Aethlon Medical reported fiscal Q3 2026 results showing continued operating losses but significant cost discipline. For the quarter ended December 31, 2025, operating expenses were about $2.06 million, up from $1.81 million a year earlier, leading to an operating loss of $2.06 million and a net loss of $2.02 million.
Over the nine months ended December 31, 2025, operating expenses fell 26.9% to about $5.36 million from $7.34 million, driven by lower payroll, general and administrative, and professional fees. Cash and cash equivalents were about $7.0 million as of December 31, 2025, with total assets of $8.06 million.
The company highlighted continued compliance with Nasdaq listing requirements, progress in its Australian oncology trial Cohort 2, advancement of its Long COVID and extracellular vesicle research, and ongoing evaluation of Hemopurifier compatibility with simplified blood treatment systems. Management noted that cash on hand may not be sufficient to support operations for the next 12 months without additional financing.
Aethlon Medical, Inc. has an effective resale registration covering up to 2,031,024 shares of common stock, issuable from previously issued warrants and pre-funded warrants held by selling securityholders. This prospectus supplement and related agreements remove the prior requirement that the pre-funded warrants receive stockholder approval before exercise, so those pre-funded warrants are now immediately exercisable, subject to beneficial ownership limits and existing terms. The underlying warrant agreements and securities purchase agreement are otherwise unchanged, and the company’s common stock continues to trade on Nasdaq under the symbol AEMD.